Triple therapy aims to shrink advanced head and neck tumors

NCT ID NCT06239220

Recruiting now Disease control Sponsor: Glenn J. Hanna Source: ClinicalTrials.gov ↗

First seen Mar 03, 2026 · Last updated May 16, 2026 · Updated 10 times

Summary

This study tests a combination of three treatments—modified immune cells (PD-L1 t-haNK), an immune-boosting protein (NAI/Anktiva), and a targeted antibody (cetuximab)—in 25 adults with advanced head and neck cancer that has returned or spread. The goal is to see if this mix can shrink tumors and control the disease. Participants must have tried immunotherapy before and have measurable tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

HEAD AND NECK CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA METASTATIC HEAD AND NECK CANCER METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA RECURRENT HEAD AND NECK CANCER RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA